Immunotherapy combo for MSI-H gastric cancer
Treatments studied
This study tests a combination of two immunotherapy drugs, ipilimumab and sintilimab, for people with a specific type of stomach or gastroesophageal junction cancer that has high microsatellite instability (MSI-H) or is mismatch repair deficient (dMMR). These drugs help the immune system fight cancer, and the goal is to see if they shrink tumors or help before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or gastroesophageal junction cancer that is MSI-H or dMMR, meaning it has specific genetic markers.
- You have either cancer that can be removed with surgery (locally advanced) or cancer that has spread and cannot be removed (unresectable or metastatic).
- You have not had any previous treatment for this cancer, such as surgery, chemotherapy, radiation, or immunotherapy.
- You are 18 years or older and your general health is good (ECOG performance status 0-1).
- Your kidney, liver, and bone marrow function are within acceptable ranges.
- You must agree to use effective birth control if there is any chance of pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) for people with advanced gastric cancer that has a specific DNA repair problem (MSI-H/dMMR). It is for those who have not yet had any treatment for their advanced cancer.
This trial tests how well immunotherapy (drugs that boost your immune system to fight cancer) works before surgery for stomach cancer that has a specific genetic marker (dMMR or MSI-H). It aims to find factors that predict response, which may lead to more personalized and effective treatment.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a new combination of IBI343, sintilimab, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated yet. It's for those whose tumors are CLDN18.2-positive and not HER2-positive.
This trial tests a combination of immunotherapy, anti-angiogenic therapy (which blocks blood vessel growth to tumors), and chemotherapy for people with a specific type of stomach cancer that is MSI-H/dMMR (meaning it has many mutations and may respond better to immunotherapy). The goal is to shrink the cancer and potentially make it removable by surgery.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.